Doxazosin Mesylate Capsules Suppliers & Bulk Manufacturers
Available Forms: Extended-release (ER) capsules
Available Strengths: 4 mg, 8 mg, and 12 mg
Reference Brands: Cardura XL
Category:
Drugs Using Osmotic Pump Systems
Cardura XL® (doxazosin mesylate) works by blocking alpha-1 adrenergic receptors, relaxing smooth muscle in blood vessels and the prostate. It reduces blood pressure and relieves urinary symptoms of BPH. Benefits include improved urinary flow, lowered hypertension, and enhanced quality of life when used as prescribed.
Doxazosin mesylate Capsules is available in Extended-release (ER) capsules
and strengths such as 4 mg, 8 mg, and 12 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Doxazosin mesylate Capsules is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Doxazosin mesylate Capsules can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Cardura XL® (doxazosin mesylate) is regulated in the EU and US, supported by dossiers demonstrating safety, efficacy, and manufacturing quality in accordance with GMP standards. In the US, FDA approval involved extensive clinical validation, safety assessments, and GMP compliance. In the EU, CE marking certifies conformity under MDR standards. These formulations undergo validation, stability testing, and audits, with detailed documentation including safety profiles, clinical trial data, and manufacturing practices.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing